KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:可得 入排置信度 0.98

Clinical Interchangeability of PD-L1 Immunohistochemistry Assays in First-Line Non-Small Cell Lung Cancer Management With Cemiplimab.

Javier Perez, Keith M Kerr, Brian Baker, Fang Fang, Jason Li, Jannine McDonald, Siyu Li, Bo Gao, Jean-Francois Pouliot, Frank Seebach, Israel Lowy, Giuseppe Gullo, Gary Herman, Jennifer Hamilton, Petra Rietschel, Kristina McGuire

JCO Precis Oncol 9 e2500177

PMID40991883
PMCIDPMC12487655
DOI10.1200/PO-25-00177
发表日期2025-09-24
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录已完成可用 Figure 视觉审查,未识别 KM 曲线。
已检查 2 张 PubMed Figure,均未识别为 KM 图:FIG 1.:AI 判定为 flow diagram;FIG 2.:AI 判定为 other。
摘要

摘要

PURPOSE: Multiple immunohistochemistry (IHC) assays targeting PD-L1 have been developed independently, and a lack of harmonization creates undue complexity for clinicians who use PD-L1 tests to guide treatment decisions. This novel bridging study demonstrates the clinical interchangeability of two PD-L1 IHC assays in first-line treatment of non-small cell lung cancer (NSCLC) with PD-L1 ≥50%. METHODS: In the phase III EMPOWER-Lung 1 study (ClinicalTrials.gov identifier: NCT03088540), 710 patients were randomly assigned 1:1 to first-line cemiplimab or platinum-doublet chemotherapy for advanced NSCLC with PD-L1 ≥50%, selected by PD-L1 IHC 22C3 pharmDx (Agilent Technologies, Santa Clara, CA). RESULTS: A total of 871 patient samples were retrospectively tested using the VENTANA PD-L1 (SP263) assay (Roche Diagnostics, Indianapolis, IN), including 481 enrolled patients and 390 patients who did not pass screening (22C3 PD-L1 <50%). Concordance of 22C3 and SP263 was evaluated in 768 patient samples, with an overall percent agreement (concordance) of 88% between the two assays. Overall survival (OS) and progression-free survival (PFS) were estimated in the PD-L1 ≥50% SP263+ population (including the 22C3+/SP263+ and 22C3-/SP263+ subpopulations). In the primary analysis, the clinical efficacy of cemiplimab versus chemotherapy in the 22C3+/SP263+ population (n = 324; OS hazard ratio [HR], 0.52 [95% CI, 0.34 to 0.80]; PFS HR, 0.43 [95% CI, 0.32 to 0.59]) was similar to that in the 22C3+ population (n = 563). A sensitivity analysis of the overall SP263+ population showed consistent results with the primary analysis. CONCLUSION: Similar efficacy (OS and PFS) was observed with the 22C3+ and SP263+ populations, demonstrating the interchangeability of these PD-L1 IHC assays for selecting patients with PD-L1 ≥50% for first-line cemiplimab monotherapy for advanced NSCLC.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIG 1.FIG 1. Study population SP263+ refers to PD-L1 expression level ≥50%, and SP263− refers to PD-L1 expression level < 50%. a The mITT population consists of 563 patients with verified PD-L1 ≥50% per testing performed according to the instructions for use, as previously reported. b A total of 871 patient samples were retrospectively tested using the VENTANA SP263 assay, including 481 patients from the ITT population and 390 patients from a randomly selected subset of patients who did not pass screening (PD-L1 <50% by Dako 22C3 per instructions for use). c The concordance population includes 768 patients with evaluable results by both the Dako 22C3 and VENTANA SP263 assays. IMP, imputed; ITT, intention-to-treat; mITT, modified intention-to-treat; NE, not evaluable.
非 KM Figure
FIG 2.FIG 2. Agreement rates between the VENTANA SP263 and Dako 22C3 assays at the ≥50% cut point. Blue dots represent concordance. Red dots represent discordance.
非 KM Figure